FRA: TKD Statistics

Total Valuation

Takeda Pharmaceutical Company has a market cap or net worth of EUR 40.75 billion. The enterprise value is 70.17 billion.

Market Cap	40.75B
Enterprise Value	70.17B

Important Dates

The next estimated earnings date is Thursday, January 30, 2025.

Earnings Date	Jan 30, 2025
Ex-Dividend Date	Mar 28, 2025

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+1.07%
Shares Change (QoQ)	+1.29%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.58B

Valuation Ratios

The trailing PE ratio is 22.46.

PE Ratio	22.46
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.19, with an EV/FCF ratio of 16.54.

EV / Earnings	38.66
EV / Sales	2.49
EV / EBITDA	8.19
EV / EBIT	17.25
EV / FCF	16.54

Financial Position

The company has a current ratio of 1.28, with a Debt / Equity ratio of 0.81.

Current Ratio	1.28
Quick Ratio	0.66
Debt / Equity	0.81
Debt / EBITDA	4.07
Debt / FCF	8.28
Interest Coverage	5.49

Financial Efficiency

Return on equity (ROE) is 4.15% and return on invested capital (ROIC) is 3.29%.

Return on Equity (ROE)	4.15%
Return on Assets (ROA)	2.77%
Return on Capital (ROIC)	3.29%
Revenue Per Employee	577,324
Profits Per Employee	36,828
Employee Count	49,281
Asset Turnover	0.31
Inventory Turnover	1.31

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -4.48% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-4.48%
50-Day Moving Average	25.34
200-Day Moving Average	25.23
Relative Strength Index (RSI)	54.57
Average Volume (20 Days)	361

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Takeda Pharmaceutical Company had revenue of EUR 28.45 billion and earned 1.81 billion in profits. Earnings per share was 1.14.

Revenue	28.45B
Gross Profit	18.76B
Operating Income	4.09B
Pretax Income	1.69B
Net Income	1.81B
EBITDA	8.31B
EBIT	4.09B
Earnings Per Share (EPS)	1.14

Full Income Statement

Balance Sheet

The company has 5.38 billion in cash and 35.11 billion in debt, giving a net cash position of -29.73 billion.

Cash & Cash Equivalents	5.38B
Total Debt	35.11B
Net Cash	-29.73B
Net Cash Per Share	n/a
Equity (Book Value)	43.32B
Book Value Per Share	27.32
Working Capital	4.17B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 5.48 billion and capital expenditures -1.24 billion, giving a free cash flow of 4.24 billion.

Operating Cash Flow	5.48B
Capital Expenditures	-1.24B
Free Cash Flow	4.24B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 65.95%, with operating and profit margins of 14.38% and 6.38%.

Gross Margin	65.95%
Operating Margin	14.38%
Pretax Margin	5.93%
Profit Margin	6.38%
EBITDA Margin	29.22%
EBIT Margin	14.38%
FCF Margin	14.91%

Dividends & Yields

This stock pays an annual dividend of 98.61, which amounts to a dividend yield of 401.16%.

Dividend Per Share	98.61
Dividend Yield	401.16%
Dividend Growth (YoY)	8,313.67%
Years of Dividend Growth	n/a
Payout Ratio	101.62%
Buyback Yield	-1.07%
Shareholder Yield	400.09%
Earnings Yield	4.45%
FCF Yield	10.41%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Takeda Pharmaceutical Company has an Altman Z-Score of 1.17. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.17
Piotroski F-Score	n/a